Manchester, UK
Mon 17 17:16
LT5
Prostate Cancer: Are Male Testosterone Assays Fit For Purpose?
Manchester, UK
London, UK
Tue 18 09:00
Novel Preclinical Models and Tools for Prostate Cancer Experimental Evolution
London, UK
Tue 18 13:30
Panel Discussion - The future of hormone-dependent cancer research: what are we missing?
London, UK
Manchester, UK
Dublin, Ireland
Newcastle Upon Tyne, UK
Tue 18 09:30
OC5
Abstract 5: A defined iPSC-derived prostate organoid model as a platform to study lineage specification and primary cilia dysfunction in prostate cancer
Newcastle Upon Tyne, UK
Glasgow, UK
Mon 17 17:20
LT6
Therapeutic potential of targeting the BCL-2 family in prostate and breast cancer tumour initiation, growth and metastasis.
Glasgow, UK
Cambridge, UK
Mon 17 10:50
OC1
Abstract 1: Uncovering regulatory dependencies in neuroendocrine prostate cancer through proteomic and targeted perturb-seq (TAPseq) profiling
Cambridge, UK
Gothenburg, Sweden
Mon 17 17:28
LT8
Baseline Sex Steroid Profiles Predict Biochemical Recurrence in High-Risk Prostate Cancer patients with N0 Disease
Gothenburg, Sweden
Lausanne, Switzerland
Mon 17 11:05
OC2
Abstract 2: Progestin Subtype Dictates Early Breast Carcinogenesis: Oncogenic Role of Androgenic Progestins
Lausanne, Switzerland
Newcastle Upon Tyne, UK
Mon 17 12:30
OC4
Abstract 4: How cross-over between hormonal and oncogenic signalling regulates glyco-immune checkpoints in prostate cancer
Newcastle Upon Tyne, UK
London, UK
Mon 17 14:45
Career Workshop - Navigating different academic career routes
Canada
London, UK
USA
Belgium
York, UK
Mon 17 17:12
LT4
Illuminating the future of Breast Cancer Therapeutics: Applying Synthetic Biology’s UV Crosslinking Amino Acids for Drug Target Discovery.
York, UK
Gothenburg, Sweden
Mon 17 12:15
OC3
Abstract 3: Adrenal-derived factors promote tumor progression and sclerotic bone lesion formation in castration-resistant prostate cancer
Gothenburg, Sweden
York, UK
Mon 17 17:32
LT9
Crosstalk Between ERα and Hypoxia Drives a Novel Transcriptional Programme and Therapeutic Vulnerability in Breast Cancer
York, UK
Manchester, UK
Tue 18 11:40
Breast cancer risk prediction and prevention in young women; a future role for progesterone receptor antagonists?
Manchester, UK
Tue 18 13:30
Panel Discussion - The future of hormone-dependent cancer research: what are we missing?
London, UK
Manchester, UK
Dublin, Ireland
London, UK
Mon 17 17:24
LT7
AKT and MCL1 co-inhibition triggers intrinsic apoptosis in PTEN-loss/PI3K-activated castration resistant prostate cancer
London, UK
Tampere, Finland
Mon 17 17:00
LT1
AR-Driven Chromatin Accessibility Diverges Between Benign and Malignant Prostate Cells
Tampere, Finland
Canada
Mon 17 10:15
Lecture: Defining androgen receptor regulatory grammar in prostate cancer
Canada
Mon 17 14:45
Career Workshop - Navigating different academic career routes
Canada
London, UK
USA
Belgium
London, UK
Tue 18 09:45
OC6
Abstract 6: Tracing the evolutionary trajectory of CDK4/6 inhibitor resistance in oestrogen receptor positive breast cancer
London, UK
Dublin, Ireland
Mon 17 11:45
Lecture: The role of androgens in breast cancer
Dublin, Ireland
Tue 18 13:30
Panel Discussion - The future of hormone-dependent cancer research: what are we missing?
London, UK
Manchester, UK
Dublin, Ireland
Tue 18 13:30
Panel Discussion - The future of hormone-dependent cancer research: what are we missing?
London, UK
Manchester, UK
Dublin, Ireland
USA
Mon 17 14:45
Career Workshop - Navigating different academic career routes
Canada
London, UK
USA
Belgium
Tue 18 14:15
Exploiting Addiction: Understanding and Targeting the Requirement for Androgen Receptor Function in Advanced Prostate Cancer
USA
Belgium
Mon 17 14:45
Career Workshop - Navigating different academic career routes
Canada
London, UK
USA
Belgium
Tue 18 10:40
Lecture: Understanding breast tumour initiation and treatment response in context of the host
Belgium
York, UK
Mon 17 17:04
LT2
Exploring Hypoxia-driven Estrogen Receptor (ER) Heterogeneity in Breast Cancer using Calling Cards
York, UK
Bristol, UK
Mon 17 17:08
LT3
RAGE against the prostate cancer: Evaluating a novel antibody-drug conjugate
Bristol, UK
London, UK
Tue 18 11:10
OC7
Abstract 7: Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
London, UK
Royal College of Surgeons in Ireland, Dublin
London, UK
Tue 18 11:25
OC8
Abstract 8: Abrogating persistent androgen receptor signalling by modulating EIF4A biology as novel therapeutic strategy in castration-resistant prostate cancer
London, UK
London, UK
Mon 17 17:36
LT10
MiR-16-5p and MiR-424-5p: Cell Cycle Regulation and Therapeutic Potential in Prostate Cancer
London, UK
Workshop
0
Oral
3
Expert
0
Plenary
0
Catering and Social
1
Nurse
0
Other
0
Symposium
0
No Session Type
19
Mon 17 10:15
Lecture: Defining androgen receptor regulatory grammar in prostate cancer
Canada
Mon 17 10:50
OC1
Abstract 1: Uncovering regulatory dependencies in neuroendocrine prostate cancer through proteomic and targeted perturb-seq (TAPseq) profiling
Cambridge, UK
Mon 17 11:05
OC2
Abstract 2: Progestin Subtype Dictates Early Breast Carcinogenesis: Oncogenic Role of Androgenic Progestins
Lausanne, Switzerland
Mon 17 11:45
Lecture: The role of androgens in breast cancer
Dublin, Ireland
Mon 17 12:15
OC3
Abstract 3: Adrenal-derived factors promote tumor progression and sclerotic bone lesion formation in castration-resistant prostate cancer
Gothenburg, Sweden
Mon 17 12:30
OC4
Abstract 4: How cross-over between hormonal and oncogenic signalling regulates glyco-immune checkpoints in prostate cancer
Newcastle Upon Tyne, UK
Mon 17 14:45
Career Workshop - Navigating different academic career routes
Canada
London, UK
USA
Belgium
Mon 17 17:00
LT1
AR-Driven Chromatin Accessibility Diverges Between Benign and Malignant Prostate Cells
Tampere, Finland
Mon 17 17:04
LT2
Exploring Hypoxia-driven Estrogen Receptor (ER) Heterogeneity in Breast Cancer using Calling Cards
York, UK
Mon 17 17:08
LT3
RAGE against the prostate cancer: Evaluating a novel antibody-drug conjugate
Bristol, UK
Mon 17 17:12
LT4
Illuminating the future of Breast Cancer Therapeutics: Applying Synthetic Biology’s UV Crosslinking Amino Acids for Drug Target Discovery.
York, UK
Mon 17 17:16
LT5
Prostate Cancer: Are Male Testosterone Assays Fit For Purpose?
Manchester, UK
Mon 17 17:20
LT6
Therapeutic potential of targeting the BCL-2 family in prostate and breast cancer tumour initiation, growth and metastasis.
Glasgow, UK
Mon 17 17:24
LT7
AKT and MCL1 co-inhibition triggers intrinsic apoptosis in PTEN-loss/PI3K-activated castration resistant prostate cancer
London, UK
Mon 17 17:28
LT8
Baseline Sex Steroid Profiles Predict Biochemical Recurrence in High-Risk Prostate Cancer patients with N0 Disease
Gothenburg, Sweden
Mon 17 17:32
LT9
Crosstalk Between ERα and Hypoxia Drives a Novel Transcriptional Programme and Therapeutic Vulnerability in Breast Cancer
York, UK
Mon 17 17:36
LT10
MiR-16-5p and MiR-424-5p: Cell Cycle Regulation and Therapeutic Potential in Prostate Cancer
London, UK
Tue 18 09:00
Novel Preclinical Models and Tools for Prostate Cancer Experimental Evolution
London, UK
Tue 18 09:30
OC5
Abstract 5: A defined iPSC-derived prostate organoid model as a platform to study lineage specification and primary cilia dysfunction in prostate cancer
Newcastle Upon Tyne, UK
Tue 18 09:45
OC6
Abstract 6: Tracing the evolutionary trajectory of CDK4/6 inhibitor resistance in oestrogen receptor positive breast cancer
London, UK
Tue 18 10:40
Lecture: Understanding breast tumour initiation and treatment response in context of the host
Belgium
Tue 18 11:10
OC7
Abstract 7: Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
London, UK
Tue 18 11:25
OC8
Abstract 8: Abrogating persistent androgen receptor signalling by modulating EIF4A biology as novel therapeutic strategy in castration-resistant prostate cancer
London, UK
Tue 18 11:40
Breast cancer risk prediction and prevention in young women; a future role for progesterone receptor antagonists?
Manchester, UK
Tue 18 13:30
Panel Discussion - The future of hormone-dependent cancer research: what are we missing?
London, UK
Manchester, UK
Dublin, Ireland
Tue 18 14:15
Exploiting Addiction: Understanding and Targeting the Requirement for Androgen Receptor Function in Advanced Prostate Cancer
USA
0 result(s) found.